Mixed models modelling
|
|
6
|
216
|
September 29, 2023
|
ITT analysis population - RCT
|
|
2
|
156
|
September 18, 2023
|
Comparing "all active dose" to placebo - do we treat "all active dose" as one group or separate groups?
|
|
2
|
188
|
September 4, 2023
|
Guidance of analysis of longitudinal patient reported outcomes w.r.t Joint models
|
|
4
|
225
|
August 29, 2023
|
Effect modification in series of n-of-1 trials (repeated crossover)
|
|
2
|
147
|
August 25, 2023
|
Individual response
|
|
234
|
30258
|
August 21, 2023
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
30
|
1441
|
August 15, 2023
|
Data collected outside of guidelines/window
|
|
10
|
338
|
June 13, 2023
|
Different results in unconstrained partial proportional odds model
|
|
0
|
392
|
May 22, 2023
|
Attrition Sensitive Randomisation
|
|
1
|
432
|
April 25, 2023
|
Randomization in a diagnostic study - necessary?
|
|
3
|
457
|
March 16, 2023
|
Appropriate model for combined data from two RCTs
|
|
10
|
428
|
March 8, 2023
|
RCT with missing follow-up outcomes: ANCOVA + MI vs Mixed-Effects Modelling?
|
|
50
|
3722
|
March 7, 2023
|
FDA "Bad Habits"
|
|
7
|
1394
|
March 4, 2023
|
Resources for handling blocked randomization in the analysis of RCTs
|
|
10
|
570
|
February 11, 2023
|
Toward Guidelines for RCT Measurements.. What are the characteristics of an acceptable measurement for RCT?
|
|
0
|
610
|
February 10, 2023
|
What is a fake measurement tool and how are they used in RCT
|
|
46
|
15122
|
January 23, 2023
|
Language for communicating frequentist results about treatment effects
|
|
197
|
103031
|
January 18, 2023
|
Rescue analysis for % change from baseline as an outcome in RCT
|
|
16
|
1337
|
January 16, 2023
|
The Clinical and Statistical Saga of Thrombolysis in Acute Ischemic Stroke
|
|
11
|
1561
|
December 21, 2022
|
Information, Evidence, and Statistics for critical research appraisal
|
|
17
|
1746
|
November 21, 2022
|
Is it appropriate to present confidence intervals (CIs) for the outcome in each treatment group in the context of clinical trials?
|
|
5
|
773
|
November 2, 2022
|
Background to PFS endpoint
|
|
19
|
6525
|
October 6, 2022
|
Quality of remdesivir trials
|
|
54
|
16704
|
October 5, 2022
|
Run-in phase in RCTs
|
|
10
|
9386
|
September 24, 2022
|
Cdisc in academia
|
|
1
|
796
|
September 7, 2022
|
Patient-specific treatment effects in RCTs: why should one present them?
|
|
1
|
1898
|
August 13, 2022
|
Analyzing compositional outcome data
|
|
5
|
3261
|
July 28, 2022
|
Which to make as the primary analysis
|
|
1
|
1847
|
July 25, 2022
|
Non-inferiority and choice of scale (absolute vs relative)
|
|
4
|
1294
|
July 23, 2022
|